Abbott Laboratories (NYSE:ABT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Abbott Laboratories has a consensus analyst rating of “Moderate Buy” from 26 covering analysts, with 19 buy ratings and an average 1-year price target of about $119.09.
• The company reported better-than-expected Q1 earnings, posting $1.15 EPS on $11.16 billion in revenue, both slightly above Wall Street estimates, while raising full-year and Q2 guidance.
• Recent developments were mostly positive, including CE Mark approval in Europe for Libre Duo, reaffirmed support for Cologuard products, and FDA/EU clearance for Ultreon 3.0, all of which could support future growth.

Shares of Abbott Laboratories (NYSE:ABT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-six analysts that are presently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $119.0870.

Several brokerages have issued reports on ABT. BTIG Research restated a "buy" rating and issued a $131.00 target price on shares of Abbott Laboratories in a report on Monday, April 27th. Barclays lowered their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research report on Monday, April 20th. Mizuho dropped their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a report on Friday, April 17th. Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Finally, Benchmark decreased their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the firm's stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company's stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Capasso Planning Partners LLC boosted its stake in Abbott Laboratories by 743.6% during the first quarter. Capasso Planning Partners LLC now owns 3,290 shares of the healthcare product maker's stock worth $338,000 after buying an additional 2,900 shares during the period. Axiom Investment Management LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $368,000. WNY Asset Management LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $694,000. Segall Bryant & Hamill LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $40,146,000. Finally, Evolutionary Tree Capital Management LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at approximately $1,834,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Stock Up 0.6%

ABT stock opened at $86.19 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average of $94.92 and a two-hundred day moving average of $110.87. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a market cap of $150.13 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 1.43 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. During the same period in the previous year, the firm posted $1.09 EPS. The business's revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott secured CE Mark approval in Europe for Libre Duo, the world’s first dual glucose-ketone sensing technology for diabetes care, which could broaden its addressable market and strengthen its diabetes device franchise. Article Title
• Positive Sentiment: The American Cancer Society reaffirmed Abbott’s noninvasive colorectal cancer screening products, Cologuard and Cologuard Plus, as preferred options for average-risk adults, supporting demand for the company’s screening portfolio. Article Title
• Positive Sentiment: Abbott also won FDA and EU clearance for its AI-powered Ultreon 3.0 software, which helps guide artery stent placement and could support growth in its cardiovascular business. Article Title
• Neutral Sentiment: Analyst-focused articles reiterated that Wall Street remains broadly bullish on Abbott, and Goldman Sachs maintained a Buy rating even after trimming its price target to $113 from $121. Article Title
• Neutral Sentiment: Commentary on Abbott’s diagnostics unit pointed to a mixed quarter, with Core Lab growth offset by China weakness and softer respiratory testing demand, suggesting uneven near-term performance in the segment. Article Title
• Negative Sentiment: Some market coverage noted that Abbott’s shares fell in a recent session despite a broader market uptick, reflecting lingering pressure even as fundamental news flow turns more favorable. Article Title

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.